Glenmark Pharmaceuticals announced the launch of its novel, patent
protected and globally]researched sodium glucose co]transporter]2 (SGLT2) inhibitor Remogliflozin
etabonate (Remogliflozin) in India. The drug is indicated in the treatment of type]2 diabetes mellitus
in adults.
SGLT2 inhibitors are novel anti]diabetic drugs that help achieve glycemic control by acting on the SGLT2 receptors in the proximal tubule of the kidney, thereby preventing renal reabsorption of glucose and promoting excretion of glucose in the urine. SGLT2 drugs provide glycemic control, induce weight loss and reduce cardiovascular risks.
Glenmark is the first company in the world to launch the novel SGLT2 inhibitor Remogliflozin and India is the first country to get access to this innovative drug. Glenmark will commercialize Remogliflozin in India under the brand names gRemoh and gRemozenh.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
